Atria Investments Inc Has $1.78 Million Stake in Haleon PLC Sponsored ADR $HLN

Atria Investments Inc lifted its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 9.5% during the second quarter, Holdings Channel.com reports. The firm owned 171,547 shares of the company’s stock after purchasing an additional 14,883 shares during the period. Atria Investments Inc’s holdings in Haleon were worth $1,779,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Private Trust Co. NA grew its holdings in Haleon by 13.3% during the second quarter. Private Trust Co. NA now owns 8,794 shares of the company’s stock worth $91,000 after buying an additional 1,032 shares in the last quarter. Apollon Wealth Management LLC grew its holdings in Haleon by 5.4% during the first quarter. Apollon Wealth Management LLC now owns 21,722 shares of the company’s stock worth $224,000 after buying an additional 1,111 shares in the last quarter. Holistic Financial Partners grew its holdings in Haleon by 9.6% during the first quarter. Holistic Financial Partners now owns 13,379 shares of the company’s stock worth $138,000 after buying an additional 1,172 shares in the last quarter. AE Wealth Management LLC grew its holdings in Haleon by 6.5% during the first quarter. AE Wealth Management LLC now owns 19,323 shares of the company’s stock worth $199,000 after buying an additional 1,186 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Haleon by 4.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 31,423 shares of the company’s stock worth $321,000 after buying an additional 1,200 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Down 0.5%

HLN stock opened at $9.34 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. The company has a market capitalization of $41.57 billion, a price-to-earnings ratio of 23.94, a PEG ratio of 2.81 and a beta of 0.20. Haleon PLC Sponsored ADR has a fifty-two week low of $8.71 and a fifty-two week high of $11.42. The stock has a fifty day moving average of $9.30 and a 200-day moving average of $9.94.

Analyst Ratings Changes

Several brokerages recently issued reports on HLN. Barclays downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday, September 16th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Wednesday, October 8th. The Goldman Sachs Group upgraded Haleon from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 10th. Finally, Wall Street Zen downgraded Haleon from a “buy” rating to a “hold” rating in a research note on Saturday, July 12th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Haleon currently has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.